Diagnostic performance of the Kaiser score in the evaluation of breast lesions on contrast-enhanced mammography

Kang, Yihe; Li, Zhigang; Guang, Yang; Xue, Jing; Zhang, Lingling; Rong, Xiaocui

doi:10.1016/j.ejrad.2022.110524

Cited by 3 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kang et al investigated whether KS could improve the diagnostic performance of the BI-RADS system in evaluating breast-enhancing lesions on CEM. They concluded that the use of the KS provided a high diagnostic performance in distinguishing malignant and benign breast lesions on CEM, outperforming BI-RADS and that the use of the KS avoided up to 47.9% of unnecessary biopsies of benign breast lesions [24]. These studies indicate that a KS-based flowchart for CEM could be a valuable diagnostic tool for breast imaging.…”

Section: Discussionmentioning

confidence: 96%

Evaluation of Contrast-Enhanced Mammography and Development of Flowchart for BI-RADS Classification of Breast Lesions

et al. 2023

View full text Add to dashboard Cite

This study aimed to evaluate contrast-enhanced mammography (CEM) and to compare breast lesions on CEM and breast magnetic resonance imaging (MRI) using 5 features. We propose a flowchart for BI-RADS classification of breast lesions on CEM based on the Kaiser score (KS) flowchart for breast MRI. Sixty-eight subjects (women and men; median age 61.4 ± 11.6 years) who were suspected of having a malignant process in the breast based on digital mammography (MG) findings were included in the study. The patients underwent breast ultrasound (US), CEM, MRI and biopsy of the suspicious lesion. There were 47 patients with malignant lesions confirmed by biopsy and 21 patients with benign lesions, for each of which a KS was calculated. In the patients with malignant lesions, the MRI-derived KS was 9 (IQR 8–9); its CEM equivalent was 9 (IQR 8–9); and BI-RADS was 5 (IQR 4–5). In patients with benign lesions, MRI-derived KS was 3 (IQR 2–3); its CEM equivalent was 3 (IQR 1.7–5); and BI-RADS was 3 (IQR 0–4). There was no significant difference between the ROC-AUC of CEM and MRI (p = 0.749). In conclusion, there were no significant differences in KS results between CEM and breast MRI. The KS flowchart is useful for evaluating breast lesions on CEM.

show abstract

Section: Discussionmentioning

confidence: 96%

Evaluation of Contrast-Enhanced Mammography and Development of Flowchart for BI-RADS Classification of Breast Lesions

et al. 2023

View full text Add to dashboard Cite

show abstract

State-of-the-art for contrast-enhanced mammography

Covington,

Salmon,

Weaver

et al. 2024

British Journal of Radiology

View full text Add to dashboard Cite

Contrast-enhanced mammography (CEM) is an emerging breast imaging technology with promise for breast cancer screening, diagnosis, and procedural guidance. However, best uses of CEM in comparison to other breast imaging modalities such as tomosynthesis, ultrasound, and MRI remain inconclusive in many clinical settings. This review article summarizes recent peer-reviewed literature, emphasizing retrospective reviews, prospective clinical trials, and meta-analyses published from 2020-2023. The intent of this article is to supplement prior comprehensive reviews and summarize the current state-of-the-art of CEM.

show abstract

Reliability of Kaiser Score in Assessing Additional Breast Lesions Identified on Staging MRI in Patients with Breast Cancer

Hijazi,

Chahine,

Berjawi

et al. 2024

Diagnostics

View full text Add to dashboard Cite

(1) Background: The Kaiser score is a user-friendly tool that evaluates lesions on breast MRI and has been studied in the general population and a few specific clinical scenarios. We aim to evaluate the performance of the Kaiser score in the characterization of additional lesions identified on staging breast MRI. (2) Methods: The Kaiser score of the biopsied additional lesions identified on staging MRI in recently diagnosed breast cancer patients was retrospectively determined. Statistical analysis was performed to evaluate the diagnostic capability of the Kaiser score and whether it is affected by different imaging and pathological parameters of the additional and the index lesion. (3) Results: Seventy-six patients with ninety-two MRI-detected lesions constitute the studied population. There was a statistically significant difference in the Kaiser score between benign and malignant lesions, irrespective of the pathology of the index cancer (p = 0.221) or the size and the imaging features of the additional lesion. Using a cutoff of 5 and above for suspicious lesions, biopsy could have been avoided in 34/92 lesions. (4) Conclusions: The Kaiser score can assist radiologists in the evaluation of additional MRI lesions identified in recently diagnosed breast cancer patients, thus decreasing the number of unneeded biopsies and delays in definitive surgical management.

show abstract

Diagnostic performance of the Kaiser score in the evaluation of breast lesions on contrast-enhanced mammography

Cited by 3 publications

References 27 publications

Evaluation of Contrast-Enhanced Mammography and Development of Flowchart for BI-RADS Classification of Breast Lesions

Evaluation of Contrast-Enhanced Mammography and Development of Flowchart for BI-RADS Classification of Breast Lesions

State-of-the-art for contrast-enhanced mammography

Reliability of Kaiser Score in Assessing Additional Breast Lesions Identified on Staging MRI in Patients with Breast Cancer

Contact Info

Product

Resources

About